For the January-March period, the company's revenue increased by 9 percent to Rs 545 crore, as against the revenue of Rs 502 crore during the year-ago quarter.
Hikal’s earnings before interest, taxes, depreciation, and amortisation or EBITDA of Rs 90 crore in the quarter under review stood 48 percent higher year-on-year compared to Rs 61 crore last March.
The company’s operating profit margin (OPM) advanced to 16.5 percent in the fourth quarter of fiscal year 2023 compared to 12.2 percent in the year-ago period.
Hikal’s pharmaceutical business' revenue remained flat at Rs 309 crore, compared to Rs 308 crore last year. On a sequential basis, revenue for this business increased by 5.8 percent. EBIT for this business increased by 20 percent year-on-year to Rs 36 crore.
The company said that it received enhanced traction from existing as well as new customers in the Contract Development and Manufacturing Organisation (CDMO) business and an improvement in product mix.
Shares of Hikal ended 8.58 percent higher at Rs 307.55.
